Shimadzu Corp.

Shimadzu Corp., a key player in the Pharmaceuticals & Biotechnology sector, saw a significant rise in stock price on June 1, 2026. Despite a year-to-date decline, the company maintains strong management efficiency with a solid return on equity and low debt-to-equity ratio, highlighting its financial stability.

Shimadzu Corp. has experienced notable stock activity, achieving an intraday high and outperforming the Japan Nikkei 225 over the past week. Despite recent gains, the company faces longer-term challenges, including a year-to-date decline. It maintains strong management efficiency, with a solid return on equity and low debt-to-equity ratio.

Shimadzu Corp., a key player in the Pharmaceuticals & Biotechnology sector, faced a significant stock decline on May 13, 2026, contrasting with the Japan Nikkei 225's gains. The company has shown consistent underperformance over various timeframes, despite maintaining strong management efficiency and a stable profit increase over the past year.

Shimadzu Corp., a key player in the Pharmaceuticals & Biotechnology sector, faced a challenging market day on May 12, 2026, with a notable decline. Despite a slight recovery over the past week, the stock has underperformed year-to-date compared to the Japan Nikkei 225, although it maintains strong management efficiency and low debt levels.

Shimadzu Corp. has seen a significant rise in stock performance, reaching an intraday high of JPY 3,848.00. The company has recorded a 5.78% increase over the past week, with a market capitalization of JPY 1,137,502 million and a price-to-earnings ratio of 20.00, reflecting its financial stability.

Shimadzu Corp. saw a significant increase in stock performance today, reaching an intraday high. However, the company has faced challenges in its longer-term metrics, with notable declines over the past month and year-to-date. Despite this, it maintains solid management efficiency and low debt levels.

Shimadzu Corp. has seen a rise in stock performance today, reaching an intraday high. However, the company has faced longer-term challenges, with declines over the past week and month, and a slight annual return. It maintains strong management efficiency and low debt, but trades at a premium compared to peers.

Shimadzu Corp., a key player in the Pharmaceuticals & Biotechnology sector, faced a significant decline in stock performance recently, contrasting with the broader market trends. Despite strong management efficiency and a premium valuation, the company reported a decrease in profits over the past year, alongside notable stock underperformance.

Shimadzu Corp., a key player in the Pharmaceuticals & Biotechnology sector, faced a significant stock decline on March 3, 2026. The company has underperformed compared to the Japan Nikkei 225 index, with notable decreases over the past week and month. Despite challenges, it maintains strong management efficiency and a low debt profile.

Shimadzu Corp. faced a decline on November 6, 2025, contrasting with the broader market's performance. The company has seen a year-to-date drop, despite maintaining strong management efficiency and low debt levels. Its stock valuation remains elevated compared to historical averages, prompting close observation from stakeholders.

Shimadzu Corp., a key player in the Pharmaceuticals & Biotechnology sector, saw its stock decline significantly on October 29, 2025. Despite a challenging trading session, the company maintains strong management efficiency with a return on equity of 10.69% and a low debt profile, although its stock valuation remains elevated.

Shimadzu Corp., a key player in the Pharmaceuticals & Biotechnology sector, saw its stock rise significantly on October 22, 2025. Despite recent gains, the company has struggled over the past year, with a notable decline, contrasting with the broader market's performance. Its market capitalization stands at JPY 1,075,623 million.

Shimadzu Corp. saw a significant decline in its stock price on October 14, 2025, contrasting with the Japan Nikkei 225's performance. Over the past week and year, the company has struggled, underperforming the index. Despite this, Shimadzu exhibits strong management efficiency and low debt levels, though its valuation remains high.

Shimadzu Corp., a key player in the Pharmaceuticals & Biotechnology sector, saw a notable rise on October 6, 2025, outperforming the Japan Nikkei 225. Despite recent gains, the company faces longer-term challenges with a year-to-date decline. It maintains strong management efficiency and low debt levels, ensuring financial stability.